The final version of our Blood Advances manuscript looking at sub-q decitabine in myelofibrosis is out!
pubmed.ncbi.nlm.nih.gov/39250708/
pubmed.ncbi.nlm.nih.gov/39250708/
November 23, 2024 at 12:46 AM
The final version of our Blood Advances manuscript looking at sub-q decitabine in myelofibrosis is out!
pubmed.ncbi.nlm.nih.gov/39250708/
pubmed.ncbi.nlm.nih.gov/39250708/
Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors 🧪 #PancreaticCancer www.sciencedirect.com/science/arti...
Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors
Pancreatic ductal adenocarcinoma (PDAC) shows limited response to chemotherapy, partly due to the absence of effective biomarkers for personalized tre…
www.sciencedirect.com
January 23, 2025 at 10:13 AM
Enhancing PDAC Therapy: Decitabine-Olaparib Synergy Targets KRAS-Dependent Tumors 🧪 #PancreaticCancer www.sciencedirect.com/science/arti...
p53 status determines the epigenetic response to demethylating agents Azacitidine and Decitabine. https://www.biorxiv.org/content/10.1101/2025.05.19.654807v1
May 20, 2025 at 4:17 AM
p53 status determines the epigenetic response to demethylating agents Azacitidine and Decitabine. https://www.biorxiv.org/content/10.1101/2025.05.19.654807v1
Still new dNTP metabolic pathways to be uncovered. Cool study to be added to the reading list 👇
www.pnas.org/doi/10.1073/...
Deamination of dCTP catalysed by CDADC1. Also looks relevant for chemotherapy drugs like gemcitabine and decitabine, whose active metabolites mimic dCTP.
www.pnas.org/doi/10.1073/...
Deamination of dCTP catalysed by CDADC1. Also looks relevant for chemotherapy drugs like gemcitabine and decitabine, whose active metabolites mimic dCTP.
CDADC1 is a vertebrate-specific dCTP deaminase that metabolizes gemcitabine and decitabine to prevent cellular toxicity | PNAS
Cancer therapy is limited by resistance to standard-of-care chemotherapeutic and/or
by treatment-associated toxicity. Identifying molecular mechani...
www.pnas.org
June 13, 2025 at 10:14 AM
Still new dNTP metabolic pathways to be uncovered. Cool study to be added to the reading list 👇
www.pnas.org/doi/10.1073/...
Deamination of dCTP catalysed by CDADC1. Also looks relevant for chemotherapy drugs like gemcitabine and decitabine, whose active metabolites mimic dCTP.
www.pnas.org/doi/10.1073/...
Deamination of dCTP catalysed by CDADC1. Also looks relevant for chemotherapy drugs like gemcitabine and decitabine, whose active metabolites mimic dCTP.
Excited to share our new study: Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV-associated gastric cancer | mBio #EBV #Epigenetics #CancerResearch #GastricCancer #DNAme #Transcriptomics
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV-associated gastric cancer | mBio
EBV+ gastric cancer contains hypermethylated DNA, and despite this distinct molecular
phenotype, there are currently no Epstein–Barr virus (EBV)-specific treatments available.
Using an FDA-approved in...
journals.asm.org
February 10, 2026 at 4:51 PM
Excited to share our new study: Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV-associated gastric cancer | mBio #EBV #Epigenetics #CancerResearch #GastricCancer #DNAme #Transcriptomics
journals.asm.org/doi/10.1128/...
journals.asm.org/doi/10.1128/...
"p53 status determines the epigenetic response to demethylating agents Azacitidine and Decitabine"
Nice to see this work finalised on @biorxivpreprint.bsky.social
Congrats to Matthew van de Pette @mrc-tu.bsky.social and colleagues.
www.biorxiv.org/content/10.1...
Nice to see this work finalised on @biorxivpreprint.bsky.social
Congrats to Matthew van de Pette @mrc-tu.bsky.social and colleagues.
www.biorxiv.org/content/10.1...
p53 status determines the epigenetic response to demethylating agents Azacitidine and Decitabine
5’-Azacitidine (Aza) and 5-Aza-2’-deoxycytidine (Dac) are widely used demethylating drugs that directly integrate into nucleic acids. They are frequently used interchangeably, surprisingly as their se...
www.biorxiv.org
May 24, 2025 at 6:35 AM
"p53 status determines the epigenetic response to demethylating agents Azacitidine and Decitabine"
Nice to see this work finalised on @biorxivpreprint.bsky.social
Congrats to Matthew van de Pette @mrc-tu.bsky.social and colleagues.
www.biorxiv.org/content/10.1...
Nice to see this work finalised on @biorxivpreprint.bsky.social
Congrats to Matthew van de Pette @mrc-tu.bsky.social and colleagues.
www.biorxiv.org/content/10.1...
🧬 New from our Lab!
Integrated transcriptomic + methylome profiling reveals that Decitabine activates the retinoic acid pathway in EBV-associated gastric cancer, uncovering how DNA demethylation reshapes viral–host signaling.
#Epigenetics #EBV #CancerResearch
www.biorxiv.org/content/10.1...
Integrated transcriptomic + methylome profiling reveals that Decitabine activates the retinoic acid pathway in EBV-associated gastric cancer, uncovering how DNA demethylation reshapes viral–host signaling.
#Epigenetics #EBV #CancerResearch
www.biorxiv.org/content/10.1...
Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer
Epstein-Barr virus associated gastric cancer (EBVaGC) accounts for ∼9–10% of gastric cancers worldwide and is defined by a distinctive molecular profile, including extreme hypermethylation of the DNA....
www.biorxiv.org
October 21, 2025 at 6:05 PM
🧬 New from our Lab!
Integrated transcriptomic + methylome profiling reveals that Decitabine activates the retinoic acid pathway in EBV-associated gastric cancer, uncovering how DNA demethylation reshapes viral–host signaling.
#Epigenetics #EBV #CancerResearch
www.biorxiv.org/content/10.1...
Integrated transcriptomic + methylome profiling reveals that Decitabine activates the retinoic acid pathway in EBV-associated gastric cancer, uncovering how DNA demethylation reshapes viral–host signaling.
#Epigenetics #EBV #CancerResearch
www.biorxiv.org/content/10.1...
Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer https://www.biorxiv.org/content/10.1101/2025.10.14.682272v1
October 15, 2025 at 6:17 AM
Integrated transcriptomic and methylome analysis reveals retinoic acid pathway activation after decitabine treatment in EBV associated gastric cancer https://www.biorxiv.org/content/10.1101/2025.10.14.682272v1
New paper explores the therapeutic potential of the epigenetic modulator Decitabine on a neurotoxin (6-OHDA) model of #Parkinsons; Improvement accompanied by a attenuation of inflammatory mediators, including TNF-α, IL-6, IL-1β, & CRP levels
pubs.acs.org/doi/abs/10.1...
pubs.acs.org/doi/abs/10.1...
April 4, 2025 at 9:56 PM
New paper explores the therapeutic potential of the epigenetic modulator Decitabine on a neurotoxin (6-OHDA) model of #Parkinsons; Improvement accompanied by a attenuation of inflammatory mediators, including TNF-α, IL-6, IL-1β, & CRP levels
pubs.acs.org/doi/abs/10.1...
pubs.acs.org/doi/abs/10.1...
In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. Full ASCERTAIN-V trial results: https://nej.md/4fpoGzl
June 3, 2026 at 9:40 PM
In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. Full ASCERTAIN-V trial results: https://nej.md/4fpoGzl
All-oral AML treatment for patients ≥75 or unfit proved promising in Phase 1-2 trial. Oral decitabine-cedazuridine shows similar efficacy to IV options. #AMLResearch PMID:42235013, N Engl J Med 2026, @NEJM @Stanford https://doi.org/10.1056/NEJMoa2510223 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2510223
No description available
doi.org
July 5, 2026 at 12:00 AM
All-oral AML treatment for patients ≥75 or unfit proved promising in Phase 1-2 trial. Oral decitabine-cedazuridine shows similar efficacy to IV options. #AMLResearch PMID:42235013, N Engl J Med 2026, @NEJM @Stanford https://doi.org/10.1056/NEJMoa2510223 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
Decitabine-Cedazuridine ve Venetoclax.
June 4, 2026 at 4:08 PM
Decitabine-Cedazuridine ve Venetoclax.
#ASH25 (Abs 47): Encouraging early results (N=21, median age 70 y) from ph2 SAVE trial of all-oral regimen: revumenib + decitabine/cedazuridine + venetoclax in ND NPM1- or KMT2A-mutated AML. 86% ORR, 81% CR/CRh. #Medsky #cansky #oncsky #AML
www.cancercommunicator.com/oral-menin-b...
www.cancercommunicator.com/oral-menin-b...
December 6, 2025 at 6:03 PM
New hope for older adults with acute myeloid leukemia (AML), a blood cancer. A combo of oral meds got FDA approval. In a study, ~42% had complete remission. Progress in treating, not just managing, disease!
FDA Approves Oral Combination Therapy for Older Adults With AML
The FDA has approved an all-oral combination therapy, Inqovi (decitabine and cedazuridine) with Venclexta (venetoclax), for adults aged 75 or older with newly diagnosed acute myeloid leukemia (AML) wh
www.fda.gov
May 14, 2026 at 8:05 PM
New hope for older adults with acute myeloid leukemia (AML), a blood cancer. A combo of oral meds got FDA approval. In a study, ~42% had complete remission. Progress in treating, not just managing, disease!
Decitabine-Cedazuridine, kanser ilerlemesini yavaşlatıyor. Normalde hap olarak yutulduğunda vücutta hemen parçalanan decitabine maddesi, yanına eklenen cedazuridine sayesinde parçalanmadan doğrudan kana karışabiliyor.
June 4, 2026 at 4:09 PM
Decitabine-Cedazuridine, kanser ilerlemesini yavaşlatıyor. Normalde hap olarak yutulduğunda vücutta hemen parçalanan decitabine maddesi, yanına eklenen cedazuridine sayesinde parçalanmadan doğrudan kana karışabiliyor.
Decitabine/Cedazuridine Plus Venetoclax sNDA Under @fda.gov Review for Newly Diagnosed AML #leusm #oncology www.onclive.com/view/decitab...
Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML
Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.
www.onclive.com
July 9, 2025 at 11:13 PM
Decitabine/Cedazuridine Plus Venetoclax sNDA Under @fda.gov Review for Newly Diagnosed AML #leusm #oncology www.onclive.com/view/decitab...
Out in Leukemia (@natureportfolio.nature.com). Hypomethylating agents (HMAs) such as decitabine are used in clinical practice for the treatment of Acute Myeloid Leukemia and expected to re-activate tumor suppressor genes de-activated by aberrant DNA methylation.
July 15, 2025 at 11:22 AM
Out in Leukemia (@natureportfolio.nature.com). Hypomethylating agents (HMAs) such as decitabine are used in clinical practice for the treatment of Acute Myeloid Leukemia and expected to re-activate tumor suppressor genes de-activated by aberrant DNA methylation.
All-oral Revumenib, Decitabine, and Venetoclax combo achieves high response rates and durable remissions in tough-to-treat AML patients.
by Issa GC, Cuglievan B (...) Kantarjian HM et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-26-01159
by Issa GC, Cuglievan B (...) Kantarjian HM et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-26-01159
June 20, 2026 at 4:39 AM
All-oral Revumenib, Decitabine, and Venetoclax combo achieves high response rates and durable remissions in tough-to-treat AML patients.
by Issa GC, Cuglievan B (...) Kantarjian HM et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-26-01159
by Issa GC, Cuglievan B (...) Kantarjian HM et 29 al. in J Clin Oncol #MedSky
👉 get more here
📖 read the article: https://ascopubs.org/doi/10.1200/JCO-26-01159
New #JITC article: T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
jitc.bmj.com/content/13/2...
jitc.bmj.com/content/13/2...
T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoad...
Background Higher levels of tumor-infiltrating lymphocytes (TILs) in breast cancers are associated with increased likelihood of pathologic complete response (pCR) to chemotherapy. DNA methyltransferas...
jitc.bmj.com
March 7, 2025 at 9:46 PM
New #JITC article: T-cell immune checkpoint inhibition plus hypomethylation for locally advanced HER2-negative breast cancer: a phase 2 neoadjuvant window trial of decitabine and pembrolizumab followed by standard neoadjuvant chemotherapy
jitc.bmj.com/content/13/2...
jitc.bmj.com/content/13/2...
July 9, 2026 at 8:43 PM
'Here, we report that mutant p53 rescued by ATO treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine by transactivating interferon regulatory factor 7 (IRF7) directly.'
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS
Mutant p53 reactivation combined with DNA demethylation kills AML/MDS cells, showing efficacy in a pilot clinical trial.
www.science.org
August 14, 2026 at 1:11 AM
'Here, we report that mutant p53 rescued by ATO treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine by transactivating interferon regulatory factor 7 (IRF7) directly.'
www.science.org/doi/10.1126/...
www.science.org/doi/10.1126/...
Finding success with demethylating drugs in preclinical models of a deadly malignancy—
Kevin B. Jones & team report on hypomethylation of CpG islands in synovial sarcoma and the use of decitabine and azacytidine in the inhibition of tumor growth: buff.ly/4RUF6aM
Kevin B. Jones & team report on hypomethylation of CpG islands in synovial sarcoma and the use of decitabine and azacytidine in the inhibition of tumor growth: buff.ly/4RUF6aM
July 14, 2025 at 1:20 PM
Finding success with demethylating drugs in preclinical models of a deadly malignancy—
Kevin B. Jones & team report on hypomethylation of CpG islands in synovial sarcoma and the use of decitabine and azacytidine in the inhibition of tumor growth: buff.ly/4RUF6aM
Kevin B. Jones & team report on hypomethylation of CpG islands in synovial sarcoma and the use of decitabine and azacytidine in the inhibition of tumor growth: buff.ly/4RUF6aM